| Oct 15 |
MAIA Biotechnology Announces Poster Presentation of Novel THIO Prodrugs at ENA 2024 Symposium on Molecular Targets and Cancer Therapeutics
|
| Sep 10 |
MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer
|
| Sep 4 |
MAIA Biotechnology to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment Conference
|
| Jul 23 |
Why SAP Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
|
| Jun 7 |
MAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDA’s Approval of a Telomerase Inhibitor Agent Therapy
|
| Jun 6 |
MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent
|
| Jun 4 |
Recent Run-Up Provides MAIA Biotechnology With Breathing Room
|
| Jun 4 |
MAIA Biotechnology Reveals New Clinical Data Showing THIO’s Strong Efficacy in Non-Small Cell Lung Cancer
|
| May 17 |
MAIA Biotechnology to Present at the BIO International Convention 2024
|
| May 16 |
MAIA Biotechnology Abstract Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
|
